2 news items
Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations
PRGO
7 May 24
presents these non-GAAP financial measures in order to provide transparency to our investors because they are measures that management uses to assess both
Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million
PRGO
25 Apr 24
programs described herein. Adverse results with respect to the Company's appeal of any material outstanding tax assessments or pending
- Prev
- 1
- Next